SCHEMBL20339474

SCHEMBL20339474

CC(C)(C)OC(=O)N1CCN(c2ccc(C(N)=O)cc2Cl)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PARP14 Q460N5 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
PBRM1 Q86U86 1/20 0.47
STS P08842 1/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
BACE1 P56817 1/20 0.45
POLB P06746 1/20 0.44
CYP2C19 P33261 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20516395 0.88 MEN1 (0.54) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL20516367 0.88 MEN1 (0.54) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL6947145 0.87 GPR119 (0.55) GPR119MEN1KMT2APARP14SMN1; SMN2
SCHEMBL10306695 0.86 KMT2A (0.52) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL354114 0.86 L3MBTL1 (0.58) GPR119MEN1KMT2APARP14SMN1; SMN2
SCHEMBL29902983 0.86 KMT2A (0.52) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL23073659 0.85 GPR119 (0.53) GPR119MEN1KMT2APARP14SMN1; SMN2
SCHEMBL20339473 0.85 SMN1; SMN2 (0.52) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL29508821 0.84 MAPT (0.55) GPR119MEN1KMT2ASMN1; SMN2HTT
SCHEMBL993225 0.84 MAPT (0.55) GPR119MEN1KMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 US disclosed
CN-110167926-B Poly-ADP ribose polymerase (PARP) inhibitors 米托布里奇公司 2022-09-13 CN disclosed
US-20220033380-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2022-02-03 US disclosed
US-11034670-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2021-06-15 US disclosed
EP-3562822-B1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE INC (US) 2021-03-10 EP disclosed
US-20200071299-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-03-05 US disclosed
EP-3562822-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Mitobridge, Inc. (US) 2019-11-06 EP disclosed
WO-2018125961-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 WO disclosed
WO-2018125961-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033380-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP11 GPR119 2909/4885MEN1 3731/4885KMT2A 1583/4885
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 GPR119 2909/4885MEN1 3731/4885KMT2A 1583/4885
US-11034670-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 GPR119 2909/4885MEN1 3731/4885KMT2A 1583/4885
US-20200071299-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP11 GPR119 2909/4885MEN1 3731/4885KMT2A 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.